FAQ
Frequent questions about MiraKind
& the KRAS-variant
Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
MiraKind will review your application once you take the eligibility survey to apply for a study. Once you have completed your survey, if you are eligible, you can directly order your KRAS-variant results, which we will share with a physician of your choice, for a fee of $195. However, participation in a study is free if you do not want to receive your results. At the completion of the study, we will conduct a webinar to communicate the research findings and answer questions from participants.
The greatest benefit to participation is knowing that you are helping to find answers that can ultimately save lives and prevent cancer. If you also choose to learn your KRAS-variant status as part of the process of participating in a study, this knowledge may help you make healthcare decisions into the future. However, whether or not you choose to learn your KRAS-variant status, we welcome you to be part of the MiraKind community where you will have access to support, education, and cutting edge research on the KRAS-variant and other inherited genetic differences associated with cancer risk.
Individual results are available for those eligible, at a cost of $295. For study participants, results are available at a discounted rate of $195 through our sister CLIA lab, MiraDx.
There is no fee to participate in a study.
Yes, our studies are all conducted under an IRB approved Protocol.
Yes, you are welcome to participate in as many studies as you wish, as long as you meet the study criteria.
All of our studies focus on developing and understanding patient-centered applications of important genetic markers. Our goal is to enhance health, well-being and prevent cancer for as many individuals as possible. We choose topics based on the most pressing research questions at the time of the study and always welcome suggestions for study topics from members of the MiraKind community.
If you participate in a study, your data will be used in that study and be kept strictly confidential. We will never share your data with others.
Please read Understanding Results to better understand what being positive, or negative for the KRAS-variant may mean for you.
Results of your genetic KRAS-variant results are >99.9% accurate. This does not indicate that you will or will not develop cancer but rather that you carry a gene mutation which is associated with an increased risk of certain cancers.
If you receive a positive test result, you should consult with your physician and a MiraKind physician will be available to provide support along the way. As well, the MiraKind community is made up of individuals who have either tested positive for the KRAS-variant and/or who have family members who have tested positive or have a history of cancer. We have created this community with the aim of supporting individuals in their healthcare decisions, to connect them with each other, and to provide MiraKind members with access to the latest research on the KRAS-variant.
Featured Webinar
The Relationship between DNA and Cancer
In this webinar, MiraKind's Founder, Dr. Joanne Weidhaas, will discuss the relationship between DNA and cancer.
